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accepted May 6, 2he role of inﬂammation in the propagation of atherosclerosis and susceptibility to cardiovascular (CV) events is well
established. Of the wide array of inﬂammatory biomarkers that have been studied, high-sensitivity C-reactive protein
(hsCRP) has received the most attention for its use in screening and risk reclassiﬁcation and as a predictor of clinical
response to statin therapy. Although CRP is involved in the immunologic process that triggers vascular remodeling and
plaque deposition and is associatedwith increased CV disease (CVD) risk, deﬁnitive randomized evidence for its role as
a causative factor in atherothrombosis is lacking.Whethermeasurement of hsCRP levels provides consistent, clinically
meaningful incremental predictive value in risk prediction and reclassiﬁcation beyond conventional factors remains
debated. Despite publication of guidelines on the use of hsCRP in CVD risk prediction by several leading professional
organizations, there is a lack of clear consensus regarding the optimal clinical use of hsCRP. This article reviews
4 distinct points from the literature to better understand the current state and application of hsCRP in clinical practice:
1) the biology of hsCRP and its role in atherosclerosis; 2) the epidemiological association of hsCRP with CVD; 3) the
quality of hsCRPas a biomarker of risk; and4) the use of hsCRPas a tool to initiate or tailor statin therapy. Furthermore,
we highlight recommendations from societies and important considerations when using hsCRP to guide treatment
decisions in the primary prevention setting. (J Am Coll Cardiol 2013;62:397–408)ª 2013 by the American College
of Cardiology FoundationInﬂammation is central to the initiation and progression of
atherothrombosis and to triggering cardiovascular disease
(CVD) events (1). Advances in vascular biology have
established the interaction of the innate immune system
with atherosclerosis (2). Clinical studies have linked chronic
inﬂammation to future CV events (3,4), and emerging
biomarkers of inﬂammation have been postulated to improve
identiﬁcation of at-risk asymptomatic patients.
Conventional risk factors in the Framingham risk score
(FRS), such as age, male sex, hypercholesterolemia, hyper-
tension, and smoking, account for most of the risk of coronary
heart disease (CHD) and have been the bedrock of risk
assessment for decades. However, approximately one-third ofHopkins Ciccarone Center for the Prevention of Heart Disease,
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013.individuals with 0 or 1 risk factor developCHD(5,6) and up to
40%of individuals with cholesterol levels below the population
average die from CHD (7). Furthermore, many CV events
occur in patients treated with statin therapy. As such, a wide
array of biomarkersdhigh-sensitivity assays detecting low
levels of C-reactive protein (CRP), genetic polymorphism
arrays, and direct imaging of subclinical atherosclerosis with
coronary artery calcium (CAC) or carotid intima-media
thicknessdhave been investigated for reﬁnement of risk
assessment and preventive therapy allocation (Fig. 1).
This paper reviews 4 distinct points from the literature to
better understand the current state and application of high-
sensitivity C-reactive protein (hsCRP) in clinical practice:
1) the biology of CRP and its role in atherosclerosis; 2) the
epidemiological association of hsCRP with CVD; 3) the
quality of hsCRP level as a biomarker of risk; and 4) the use of
hsCRP as a tool to initiate or tailor statin therapy. Further-
more, we highlight recommendations from societies and
important considerations when using hsCRP to guide treat-
ment decisions in primary prevention.
Is hsCRP a Maker or Marker of CVD?
CRP was ﬁrst discovered in 1930 through a reaction with the
somatic C polysaccharide of Streptococcus pneumonia in patients
Figure 1 Utility of Biomark
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398afﬂicted with pneumonia (8). Its
link to CHD was reported more
than 60 years later (9). CRP has
been prodigiously investigated,
largely facilitated by its relative
stability as a frozen sample, long
plasma half-life of 19 h, and ease
of testing with a standardized
assay (10).
CRP is an acute-phase reac-
tant and nonspeciﬁc marker of
inﬂammation, produced predom-
inantly in hepatocytes as a pen-
tamer of identical subunits in
response to several cytokines (11).
Interleukin (IL)-6, one of the
most potent drivers of CRP
production, is released from acti-
vated leukocytes in response toinfection or trauma and from vascular smooth muscle cells in
response to atherosclerosis. CRP directly binds highly
atherogenic oxidized low-density lipoprotein cholesterol
(LDL-C) and is present within lipid-laden plaques (2).
The possible mechanistic role of CRP in plaque deposi-
tion is highly complex, exerting proatherogenic effects in
many cells involved in atherosclerosis (12). CRP may facil-
itate monocyte adhesion and transmigration into the vessel
wallda critical early step in the atherosclerotic process (13).
Furthermore, M1 macrophage polarization, catalyzed by
CRP, is a proinﬂammatory trigger in plaque deposition,
leading to macrophage inﬁltration of both adipose tissue and
atherosclerotic lesions (14).ers in the Lifelong Prevention of Cardiova
, and imaging biomarkers may be used in the lifelon
exposure and genetic predisposition (A) Imaging biom
lier stages of atherosclerosis before the presence of c
tients with unstable angina (C). Figure illustration byBeyond its role in triggering immunity in plaque depo-
sition, in vitro studies have also shown an association among
CRP, inhibition of endothelial nitric oxide synthase, and
impaired vasoreactivity (15,16). An isoform of CRP,
monomeric CRP, is stimulated by platelet activation and has
prothrombotic and inﬂammatory properties of its own (17).
Monomeric CRP has also been found in plaques, particu-
larly in regions of monocyte-mediated inﬂammatory activity,
and within lipid microdomains of endothelial cells (18).
In humans, treatment with statin therapy reduces levels of
both LDL-C and CRP, and concurrently there is a reduc-
tion in the number of CV events (19–22). The earliest
evidence stems from the CARE (Cholesterol and Recurrent
Events) trial, a secondary prevention trial of patients with
post–myocardial infarction (MI) in which pravastatin
reduced CRP levels independently of the magnitude of
LDL-C reduction (22). Early interpretations of such
evidence have suggested that statins have pleiotropic effects
that might contest a potential causal role of CRP in
atherosclerotic CV events (20–22).
Challenging a causative role of CRP in athero-
thrombosis. A meta-regression analysis of nearly 82,000
patients that compared clinical outcomes of lowering LDL-C
levels from 10 statin trials versus 9 nonstatin trials showed
a 1:1 relationship between LDL-C lowering and CHD and
stroke reduction during 5 years of treatment (23). This
challenges the idea that pleiotropic effects of statins
contribute additional CV risk reduction beneﬁt beyond that
expected from the degree of LDL-C lowering. Indeed, some
evidence suggests that the previously described proathero-
genic effects of CRP may have been overstated because of
contamination from endotoxins and use of preservatives inscular Disease
g prevention of atherosclerosis. Genetic and serum biomarkers may be useful in
arkers may be useful in detecting subclinical disease. (B) Circulating biomarkers may
ardiovascular disease, although high-sensitivity C-reactive protein has been shown to
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399commercial CRP assays (24). Additionally, some basic
science research disputes the direct atherogenic effects of
CRP. Transgenic overexpression of CRP in mice and in vivo
injection of large doses of human CRP have minimal effect
on inﬂammation and atherosclerosis (25–29). In another
study, transgenic rabbits with low and high CRP expression
fed a high-cholesterol diet experienced similar coronary and
aortic atherosclerosis (30).
Furthermore, large-scale Mendelian randomization anal-
yses of polymorphisms in the CRP gene have shown marked
elevations in CRP concentrations without an increased risk of
CHD (31–33). A genome-wide association analysis of more
than 66,000 participants identiﬁed 18 loci associated with
CRP levels and involved in pathways of metabolic syndrome,
immune response, and chronic inﬂammation (34). Using
a weighted genetic risk score, which explained approximately
5% of the variation in CRP levels, the researchers found
marked differences in CRP levels but no association with
CHD. This study is the latest and largest genome-wide
association study failing to demonstrate a signiﬁcant associa-
tion between genetically elevatedCRP levels and risk ofCHD.
Last, a recent meta-analysis of 46,557 patients with CHD
and 147,861 controls demonstrated a null association among
CRP-related genotypes, traditional risk factors, and risk of
CHD (33). These animal and human genetic data indicate
a lack of causal relationship between CRP and CHD. In
contrast, similar Mendelian analyses of LDL-C and lip-
oprotein(a) are compatiblewith causal effects inCHD(35,36).Association Between hsCRP and Risk for CVD
hsCRP and CVD risk in men. An association of hsCRP
with risk for CVD has been described in many studies (37).
The MRFIT (Multiple Risk Factor Intervention Trial) was
the ﬁrst of many primary prevention, prospective epidemi-
ological studies to show a strong relationship between levels
of hsCRP and mortality from CHD in high-risk middle-
aged men (9). A similar association between increasing
hsCRP levels and subsequent rate of MI and stroke was
found in an analysis of apparently healthy men (38).
hsCRP and CVD risk in women. In the WHS (Women’s
Health Study), LDL-Cdan established causative biological
marker of atherosclerosisdwas compared with hsCRP in
27,939 healthy women who were followed for an average of
8 years for MI, ischemic stroke, coronary revascularization,
or CV death. After adjustment for age and conventional risk
factors, hsCRP was a stronger predictor of CV events than
LDL-C. The primary endpoint was twice as likely in those
with hsCRP in the fourth quintile between 2.10 and
4.19 mg/l as compared with levels of 0.49 mg/l (relative risk
[RR]: 2.0; 95% CI: 1.3 to 3.0). LDL-C levels in the fourth
quintile (132 to 154 mg/dl) had a 30% excess risk of CV
events as compared with those with LDL-C <96 mg/dl
(RR: 1.3; 95% CI: 1.0 to 1.7).
The RR of CV events with each increasing quintile of
hsCRP was greater as compared with LDL-C. Women inthe high hsCRP and low LDL-C group were at greater
absolute risk than the subgroup with low hsCRP and high
LDL-C levels. Screening for both biological markers
provided better prognostication than either alone (39).
Early expert opinions on hsCRP testing in primary
prevention. In 2002, an expert panel recommended against
routine testing of hsCRP in primary prevention but supported
selective screening in individuals at an intermediate (10% to
20%) risk for mortality fromCHDor nonfatalMI in 10 years.
A literature-based meta-analysis of 22 studies was performed
on behalf of the U.S. Preventive Services Task Force to
determine whether hsCRP testing should be incorporated
into current guidelines as an adjunctive screening tool for
CHD. An hsCRP level >3 mg/l was independently associ-
ated with a 60% excess risk in incident CHD as compared
with levels <1 mg/l (RR: 1.60; 95% CI: 1.43 to 1.78) after
adjustment for all Framingham risk variables (40). Based on
the available evidence at that time, the panel concluded that
the effects of intensive treatment in those stratiﬁed as high risk
on the basis of hsCRP testing were uncertain and recom-
mended against routine testing (41).
Quality of hsCRP as a Biomarker
Standard hsCRP assays sufﬁce in settings of active infection,
tissue injury, or acute inﬂammation, which are known to
cause marked elevations. However, in the chronic setting,
the variability of standard hsCRP assays remains about as
consistent as systolic blood pressure (SBP) and total
cholesterol on a year-to-year basis (42). CV risk assessment
requires a more sensitive assay, hsCRP, which can accurately
detect very low levels of CRP in healthy individuals.
Variability among individuals. The interplay of CRP
genetic polymorphisms, inﬂuence of genetic loci mediating
CRP response, and lifestyle factors contributes to individual,
ethnic, and sex-related variation in hsCRP concentration. A
uniform cut point for hsCRP based on a single value should
not be applied universally among all individuals. Body mass
index, metabolic syndrome, diabetes mellitus, hypertension,
oral contraceptive use, physical exercise, moderate alcohol
consumption, periodontal disease, dietary patterns, envi-
ronmental pollutant burden, and smoking cause signiﬁcant
baseline variation (43).
Furthermore, there is great variability in hsCRP levels
among ethnicities, with the highest levels generally found in
African Americans, followed by Hispanics, South Asians,
whites, and East Asians, respectively. An analysis of 8,874
patients from the National Health and Nutrition Exami-
nation Survey (NHANES) database demonstrated hsCRP
levels that ranged from 0.1 to 296 mg/l (mean 4.3; median
2.1). hsCRP levels are higher among women than men and
increase with age. The mean hsCRP level was 3.5 mg/l in
20- to 29-year-old versus 5.7 mg/l in 70- to 79-year-old
individuals (44).
There is also signiﬁcant heterogeneity between sexes in
the association of hsCRP with CVD. The magnitude of
Yousuf et al. JACC Vol. 62, No. 5, 2013
High-Sensitivity CRP and Cardiovascular Disease July 30, 2013:397–408
400hsCRP’s association with CHD may be less in women
compared with men (45). In the largest analysis to date,
discrimination by hsCRP in at-risk individuals was limited
to men. Furthermore, the net improvement in risk reclas-
siﬁcation with the use of hsCRP was 1.24% for men and
only 0.38% for women (45).
Technical and biological variability. A recent examination
of a subset of the NHANES database showed signiﬁcant
short-term intraindividual variation in hsCRP levels (46). A
high coefﬁcient of variation of 46.2% (95% CI: 42.9% to
49.3%) was seen between the 2 hsCRP measurements 19
days apart. Nearly 32% of patients who were initially cate-
gorized as having elevated hsCRP levels were reclassiﬁed as
having normal levels after the second check (46). In another
recent analysis from the MESA (Multi-Ethnic Study of
Atherosclerosis) trial, 54% of individuals in the middle ter-
tile of hsCRP values had discordant levels on follow-up.
Additionally, 69% of individuals with baseline hsCRP
>3 mg/l were reclassiﬁed into a lower risk category on
subsequent measurements (47). Use of single hsCRP
measurements to risk-stratify patients may misclassify
a signiﬁcant number of individuals.
Phenotypes that portend accelerated atherosclerosis,
including metabolic syndrome, obesity, and insulin resis-
tance, are associated with elevated levels of hsCRP. In
addition to cells in atherosclerotic plaques, adipose tissue is
a signiﬁcant source of IL-6, which may explain the robust
association between hsCRP and obesity (40,48). In the
Dallas Heart Study, obesity modiﬁed the association
between hsCRP and atherosclerosis, such that increasing
levels of hsCRP were no longer associated with CAC, aortic
wall thickness, and plaque burden in obese patients (49).
Analyses from the MESA trial also suggested that the
biological association between hsCRP and coronary ath-
erosclerosis is largely accounted for by obesity (50).
Is there an ideal level of hsCRP to deﬁne increased CV
risk? Analyses from large-scale clinical trials have used
a hsCRP cut point of 2 mg/l for deﬁning increased CV risk
(21,51). A MESA analysis of 6,722 individuals demon-
strated a mean hsCRP level of 3.76 mg/l, which did
signiﬁcantly differ between those with and without future
coronary events (52). Even among those with LDL-C <130
mg/dl, for whom the use of hsCRP has been advocated by
some, there was no association between hsCRP levels and
CVD (53). Similarly, in the St. Francis Heart Study, hsCRP
was not a predictor of CV events (median 1.8 mg/l) (54).
More than 50% of all adults and 41% of 20-year-olds in the
United States have hsCRP levels >2 mg (44).
On the other hand, studies have more consistently shown
hsCRP’s association with CV events above levels of 3 mg/l
compared with reference values of <1 mg/l (55–57). In the
MESA trial, in which an hsCRP threshold of 2 mg/l
performs poorly, there is still an approximately 50% increase
in risk comparing values of >3 mg/l with those <1 mg/l
(55–57). Thus, an hsCRP threshold of 2 mg/l to inform risk
assessmentdas advocated by somedmay be misguided.hsCRP in the context of other markers of inﬂammation
and risk for CVD events. The Emerging Risk Factor
Collaboration (ERFC) reviewed the association among
hsCRP levels, CV risk factors, and vascular risk in 160,309
individuals from 54 prospective studies (48). In a total of
27,769 patients who suffered fatal or nonfatal events, hsCRP
concentration was associated with increased risk to a similar
magnitude across outcomes, including CHD (RR: 1.68;
95% CI: 1.59 to 1.78), ischemic stroke (RR: 1.46; 95% CI:
1.32 to 1.61), and death from vascular (RR: 1.82; 95% CI:
1.66 to 2.00) and nonvascular causes, such as cancer, chronic
lung disease, and injury (RR: 1.55; 95% CI: 1.46 to 1.66)
(48). This risk is similar to that seen for hyperlipidemia.
Not surprisingly, hsCRP levels were also associated with
a number of other inﬂammatory markers, including ﬁbrin-
ogen levels, leukocyte count, albumin levels, and erythrocyte
sedimentation rate. After adjustment for conventional risk
factors and ﬁbrinogen levels, the association with risk-
attenuated hsCRP levels was modestly associated with
CHD (RR: 1.23; 95% CI: 1.07 to 1.42), ischemic stroke
(RR: 1.32; 95% CI: 1.18 to 1.49), and vascular mortality
(RR: 1.34; 95% CI: 1.18 to 1.52).
Incremental value of hsCRP in risk prediction. A
biomarker capable of discriminating events independent of
conventional risk assessment would require a robust corre-
lation with CVD and marked heterogeneity (less collin-
earity) with FRS variables. hsCRP’s association with CVD is
likely, in part, a function of its strong correlation with
traditional risk factors, such as smoking, diabetes, visceral
obesity (58), and markers of inﬂammation (59,60). The
same hsCRP concentration in 2 individuals with distinct risk
factors can predict a markedly different absolute risk of
CVD (Fig. 2).
There are conﬂicting data regarding the incremental value
of hsCRP for the prediction of ﬁrst CV events. Although
some studies have shown modest improvement in predictive
ability (61,62), others have found little or no incremental
value of adding hsCRP to conventional risk factors
(39,42,63–70). Most recent studies have applied the
C-statistic or area under the receiver-operating curve (AUC)
as metrics of discrimination. To signiﬁcantly improve pre-
dictive accuracy, an increase in the C-statistic or AUC with
the addition of hsCRP to traditional risk factors may require
an odds ratio of 7 between the high and low quartiles of
hsCRP (68). A moderate improvement in predictive ability
requires an increase in the C-statistic by 0.05 (68). No
biomarker to date has achieved a RR of this magnitude
except CAC (71).
The largest C-statistic improvement was seen in a study
of 3,435 middle-aged European men, in whom the addition
of hsCRP level to the FRS increased the C-statistic by 0.015
(67). Recently, investigators from the ERFC performed an
analysis of 246,669 individuals from 52 studies. The addi-
tion of hsCRP and ﬁbrinogen levels to a prediction model
that included age, smoking status, total and high-density
lipoprotein cholesterol, and history of diabetes increased
Figure 2 Cardiovascular Risk Prediction Using hsCRP
Absolute 10-year cardiovascular disease risk in 2 distinct individuals with the same high-sensitivity C-reactive protein (hsCRP) level using Reynolds risk score.
CHD ¼ coronary heart disease; HDL ¼ high-density lipoprotein; SBP ¼ systolic blood pressure.
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401the C-statistic by 0.0039 and 0.0027, respectively (45).
Furthermore, upon exploratory analysis, hsCRP’s discrimi-
natory beneﬁt was limited to men.
A recent report of 1,330 intermediate-risk patients from
the MESA cohort showed that among various novel labo-
ratory and imaging biomarkersdCAC, carotid intima media
thickness, ankle-brachial index, brachial ﬂow–mediated
dilation, hsCRP, and family history of CHDdCAC had the
strongest association with CHD (hazard ratio [HR]: 2.60;
95% CI: 1.94 to 3.50; p < 0.01) and risk discrimination over
FRS (AUC improved from 0.623 to 0.784) in at-risk indi-
viduals (71). In comparison, hsCRP’s association was of
borderline statistical signiﬁcance (HR: 1.28; 95% CI: 1.00 to
1.64; p ¼ 0.05) and showed the least increment in CHD
risk prediction, with an AUC improvement from 0.623 to
0.640 (71).
In another recent analysis comparing several novel risk
markers, investigators from the Rotterdam Study found that
the addition of CAC scores to FRS provided the most
robust improvement in discrimination, with an increase in
the C-statistic by 0.05. Conversely, the addition of CRP did
not change the C-statistic (72).
The Reynolds risk score (RRS) adds hsCRP level and
family history to conventional parameters considered in the
FRS. Although both scores are predictive of disease risk, the
RRS has been shown in the MESA cohort to add additional
predictive power for predicting atherosclerosis progression
when discordance exists between the two scoring systems
(73). Moreover, this difference was largely driven by recali-
bration of the traditional risk variables in RRS. Family
history contributed a small amount and hsCRP even less. In
the original validation study of RRS, hsCRP was also one of
the smallest contributors to the risk stratiﬁcation algorithm
behind other factors such as age, glycated hemoglobin A1c,
smoking, SBP, and cholesterol (74). A doubling of hsCRPlevel from the population mean leads to equivalent increase
in risk as a rise in SBP of approximately 3 mm Hg in the
RRS equation.
Reclassiﬁcation of risk with hsCRP. Ultimately, the most
clinically relevant factors may be those that reclassify patients
into a more accurate risk category, presumably leading to
more appropriate treatment decisions. Classically, those with
the highest risk (i.e., 10-year risk >20%) are treated to
aggressive LDL-C goals, with lipid-lowering therapy in
addition to lifestyle modiﬁcations, whereas those with lower
risk (i.e., 10-year risk <10%) are not treated as aggressively.
In patients at low 10-year risk, elevated hsCRP levels do
not signiﬁcantly increase the CV risk above that predicted by
risk factors alone (39,63,67). Likewise, a low hsCRP level in
patients at high risk does not markedly reduce risk, given its
poor sensitivity (and thus low negative predictive value) (39).
Although there is some modulation of risk in those with low
or high 10-year risk, it often does not translate into
a meaningful change in clinical management (68). Clinicians
are left to struggle with intermediate-risk patients because
there is no clear consensus on the use of statins in this group.
A biomarker is most valuable if it reclassiﬁes intermediate-
risk patients who remain free of events into lower-risk
categories and those who will suffer events into higher-risk
groups.
Performance of hsCRP in reclassifying intermediate-risk
patients. When hsCRP level is added to FRS, the totality of
evidence suggests a modest beneﬁt in reclassiﬁcation of risk
for initially intermediate-risk patients. In the WHS, of the
20% of intermediate-risk individuals, nearly 75% of them
were reclassiﬁed into a lower-risk cohort and 4% (<0.5% of
the total population) into higher-risk (75)da transition that
is most likely to alter clinical management in those not on
statin therapy. In a study of German men with CRP >3.0
mg/l, individuals with an initial 10-year FRS of 15% to 19%
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CRP levels. However, CRP level did not reclassify those with
a 10-year predicted risk of 10% to 14% (67).
Net reclassiﬁcation improvement with hsCRP testing.
Using hsCRP level in the FraminghamHeart Study (65), the
net reclassiﬁcation improvement (NRI)dan index of the net
number of correct reclassiﬁcationsdwas 11.8% (p¼ 0.009) for
CHD and 5.6% (p¼ 0.014) for total CVD (76). Similarly, an
analysis of the WHS yielded an NRI of 5.7% (75).
Incorporating both hsCRP level and family history into
the RRS reclassiﬁed 7.6% of initially intermediate-risk men
into a higher-risk category (74). Similar ﬁndings have also
been shown in women (61). Investigators from the
Swedish Malmö Diet and Cancer Study demonstrated
reclassiﬁcation of 16% of intermediate-risk individuals;
correct reclassiﬁcation was almost entirely attributed to
down-classiﬁcation into the low-risk category. The NRI was
not signiﬁcant for CV and coronary events (70). In the
largest analysis of screening with hsCRP in preventing ﬁrst
CV events, the ERFC reclassiﬁed 1.52% of intermediate-
risk individuals (45).
Two recent reportsdfrom the Rotterdam Study and the
MESA cohortdcomparing several laboratory and imaging
biomarkers, demonstrated an NRI of 2% (with no change in
C-statistic) and 7.9% with the addition of hsCRP, respec-
tively (71,72). As a comparison, the NRI was 19.3% and
65.9% with the addition of CAC to FRS, respectively.
hsCRP as a Tool to Target Therapy:
Initiation and Intensiﬁcation
Beyond use as an adjunctive tool in risk prediction and
reclassiﬁcation, there is interest in using hsCRP levels to
select patients for statin initiation and to tailor the intensity
of therapy.
Use of hsCRP in statin initiation. In a post hoc analysis
of the AFCAPS/TexCAPS (Air Force/Texas Coronary
Atherosclerosis Prevention) primary prevention trial (77),
individuals with “low” LDL-C (<149 mg/dl) and elevated
hsCRP (>1.6 mg/l) had a 42% RR reduction (RRR
[p ¼ 0.04]) with lovastatin compared with placebo. In
contrast, individuals with LDL-C <149 mg/dl and
hsCRP <1.6 mg/l had a very low event rate and no beneﬁt to
lovastatin over placebo (p¼ 0.74). It was concluded that high
hsCRP level unmasked a group of individuals that would be
responsive to lipid-lowering therapy. These results thus gave
rise to the use of 2 mg/l as the hsCRP threshold of risk and
bolstered the rationale for no low hsCRP arm in the subse-
quent JUPITER (Justiﬁcation for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin)
trial (51). However, analysis using preferred statistical tests
for a treatment-subgroup interaction in the AFCAPS/
TexCAPS trial did not corroborate the initial ﬁndings (chi-
square heterogeneity ¼ 6.01; p ¼ 0.305) (24). Similarly, in
the PROSPER (Prospective Study of Pravastatin in the
Elderly at Risk) analysis of 5,804 elderly individuals, a CRPgroup by treatment interaction was not present. hsCRP levels
minimally enhanced risk prediction (3.64 mg/l in those who
had a CV event vs. 3.01 mg/l in those who remained event
free). Moreover, hsCRP did not predict response to therapy
with pravastatin (78).
Interpreting the JUPITER trial. It was not until the
JUPITER trial that hsCRP’s potential role in CVD
prevention became more recognized. The JUPITER trial
randomized 17,802 middle-aged to elderly low to interme-
diate risk patients with LDL-C <130 mg/dl and hsCRP
>2 mg/l to rosuvastatin 20 mg versus placebo (51). The trial
was stopped early due to a robust 44% RRR (95% CI: 31%
to 54%; p < 0.00001) in the primary endpoint of MI, stroke,
revascularization, hospitalization for unstable angina, or
death. There were 50% and 37% reductions in LDL-C and
hsCRP levels in the rosuvastatin arm, respectively.
A pre-speciﬁed analysis showed that the lowest number of
CV events were in those who achieved both a low LDL-C
and low hsCRP level. This was consistent with observa-
tional data from the ARIC (Atherosclerosis Risk in
Communities) study, in which JUPITER-eligible patients
with hsCRP >2 mg/l had a higher risk of CV events than
individuals with low hsCRP level (79).
JUPITER is often categorized as a biomarker or screening
trial; however, it is still controversial whether an elevated
hsCRP level is sufﬁcient to identify individuals who may
beneﬁt from statin therapy (80–82). A lack of a low LDL-
C/low hsCRP arm makes it impossible to exclude rosuvas-
tatin’s beneﬁt among at-risk middle-aged and elderly adults,
irrespective of the hsCRP level. The average individual in
the JUPITER trial had an FRS of 11% and a mean LDL-C
of 104 mg/dl. A prior meta-analysis of statin trials showed
that statins produce a similar proportional reduction in CV
risk across all levels of the absolute risk, even in those with
LDL-C as low as 80 mg/dl (83).
Indeed, hsCRP did not seem necessary for treatment
beneﬁt in a post hoc analysis from the HPS (Heart
Protection Study) of 20,536 individuals at risk for vascular
events who were randomized to simvastatin 40 mg versus
placebo. Statin treatment was associated with a proportional
reduction in the number of CV events, irrespective of
hsCRP levels. Even among those with hsCRP levels <1.25
mg/l, there was a 29% reduction in the number of major
vascular events (84).
A post-hoc Food and Drug Administration (FDA)
analysis of the JUPITER data performed by Kaul et al. (80)
demonstrated an inverse relationship between hsCRP levels
and clinical response to statin therapy. There was a modestly
greater relative beneﬁt from rosuvastatin in those with
hsCRP below the median cut point of 4.2 mg/l versus above
4.2 mg/l (RRR: 58% vs. 29%, respectively; p ¼ 0.015)
(Fig. 3) (80). Similar ﬁndings were observed in a post hoc
analysis by the JUPITER investigators (85). There was
a 37% RRR with rosuvastatin in the primary outcome in
men with hsCRP >5.4 mg/l versus 57% (p ¼ 0.02) in those
with hsCRP between 2.0 and 3.1 mg/l (p ¼ 0.003) (Fig. 3).
Figure 3 Treatment Effect by hsCRP in the JUPITER Trial
Treatment effect by hsCRP categories in the JUPITER trial. Compared with placebo, rosuvastatin reduced cardiovascular events in all hsCRP categories. Reprinted with
permission from Kaul et al. (80). Abbreviation as in Figure 2.
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403Further analysis by the FDA with hsCRP cut points
above and below 4 mg/l and 3 mg/l demonstrated a consis-
tent RRR with rosuvastatin across the 3 hsCRP cut points
and no change in event rates in the placebo arm (Fig. 3)
(80). An elevated hsCRP concentration did not indepen-
dently predict a preferential beneﬁt to statin therapy. No
signiﬁcant interaction between hsCRP and treatment with
statin was observed in the JUPITER trial on the basis of this
analysis (p ¼ 0.15).
The post hoc analysis by the JUPITER investigators
demonstrated a linear relationship between increasing entry
hsCRP thresholds and absolute risk of the combined
endpoint of primary outcome and mortality (Fig. 4) (85).
However, rosuvastatin-treated men with hsCRP 4, 6,
and 10 mg/l all had very similar occurrences in the primary
outcome (Fig. 5).
The JUPITER investigators concluded that the high
background event rate seen in the trial was attributable to
elevated hsCRP levels and not underlying traditional risk
factors. However, data analyzed by the FDA found that the
treatment response was only present in those with elevated
hsCRP levels and at least 1 traditional risk factor (HR: 0.51;
95% CI: 0.41 to 0.64) and not in those with an elevated
hsCRP level alone (HR: 0.91; 95% CI: 0.56 to 1.46;
pint ¼ 0.03) (80)dcorroborating the signiﬁcance of global
risk factors and the robust link between absolute risk and
beneﬁt from statins. Moreover, hsCRP levels have been
shown to increase with age, and thus, JUPITER may be an
applicable primary prevention trial of older adults (mean age
66 years) with metabolic syndrome traits.
Fueling this debate further, a recent analysis of the
ASCOT-LLA (Anglo-Scandinavian Cardiac Outcome
Trial–Lipid Lowering Arm) study of atorvastatin 10 mgversus placebo for primary prevention demonstrated that the
addition of hsCRP level to the traditional FRS only mini-
mally improved prediction of CV events (86). Although
baseline hsCRP and LDL-C levels were signiﬁcantly
predictive of CV events (odds ratio: 1.19 and 1.31, respec-
tively), baseline hsCRP levels did not predict the magnitude
of the atorvastatin response in reducing the number of
CV events (86).
Intensifying treatment: using hsCRP as a therapeutic
target. Inﬂammation substudies from 2 secondary preven-
tion trialsdPROVE IT–TIMI 22 (Pravastatin or Ator-
vastatin Evaluation and Infection Therapy–Thrombolysis
In Myocardial Infarction 22) (21) and REVERSAL
(Reversing Atherosclerosis with Aggressive Lipid Lowering)
(20)dhave shown that intensive therapy with atorvastatin
80 mg compared with pravastatin 40 mg achieved a greater
reduction in LDL-C and hsCRP levels, and together, they
are associated with a greater reduction in the number of
clinical events and progression of atherosclerotic plaque
burden. Patients who had LDL-C <70 mg/dl and
hsCRP <1 mg/l on atorvastatin had the lowest rate of
adverse CV events. Atorvastatin reduced hsCRP and LDL-
C levels by 38% and 35%, respectively (21). These ﬁndings
were conﬁrmed, albeit to a lower magnitude, in the Z phase
of the A to Z trial, in which on-treatment hsCRP levels
were independently associated with long-term survival (87).
At the population level, on-treatment hsCRP levels were
reduced by 26% and 37% in the ASCOT and JUPITER
trials, respectively. In the ASCOT trial, lower on-statin
LDL-C level at 6 months had nearly a 60% reduction in
the number of subsequent CV events compared with those
above and below the median. In contrast, hsCRP levels
above and below the median of 1.8 mg/l was not predictive
Figure 4 Relationship Between hsCRP and Treatment Arm in the JUPITER Trial
Relative risk reduction seen with rosuvastatin with increasing hsCRP thresholds (left). A linear association is shown between increasing levels of hsCRP and absolute risk of the
combined primary endpoint and mortality among (A) men and (B) women in the placebo arm (right) of the JUPITER trial. Reprinted with permission from Ridker et al. (85).
Abbreviations as in Figures 2 and 3.
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404of events. Adding hsCRP to LDL-C did not improve
prediction in response to statin therapy (86). As many as
30% to 40% of patients may see no change or an increase in
on-treatment hsCRP levels (88).
Is hsCRP a Deal Maker or Breaker
in Clinical Practice?
In the quest for individualized medicine, biomarkers have
emerged as a tool for improved risk prediction. Various
statistical measures of risk prediction improvement and risk
reclassiﬁcation indices have been used; however, no single
index tells the whole story. The American Heart Association
has laid out a framework for the comprehensive evaluation
of a novel biomarker (89). An ideal biomarker should
demonstrate quantitative differences in patients with and
without disease. Further, it should have predictive value in
prospective studies and incremental beneﬁt over standard
clinical risk markers. The goal of measuring a biomarker
should not only be risk assessment but rather ascertaining
information that would alter the threshold of the pre-test
risk to change clinical management in a cost-effective
manner. The ideal risk marker should demonstrate these
features with rigorous evidence and independence (89).
hsCRP continues to be tested routinely, despite its
difﬁcult and controversial value in guiding treatmentdecisions. The association between elevated hsCRP levels
and CVD is well established. Further, the literature also
modestly supports the incremental value that hsCRP may
have to current risk prediction models. However, reclassiﬁ-
cation of intermediate-risk patients with the addition of
hsCRP to existing FRS variables does not meaningfully alter
clinical management. Last, there is inconclusive evidence
that reducing hsCRP levels prevents CHD.
Proponents of hsCRP justify its use as a screening tool
based on the ﬁndings of the JUPITER study. However,
JUPITER was not a true biomarker trial because there was
no low hsCRP arm. It is unclear whether randomly selected
intermediate-risk patients beneﬁt from intensive treatment
on the basis of elevated hsCRP levels. Despite the abun-
dance of literature, there are no randomized data to conﬁrm
that intensifying therapy with or without hsCRP testing
changes outcomes.
Patients with LDL-C levels <130 mg/dl most likely will
have a net beneﬁt to statin therapy with or without elevated
hsCRP levels. Treating everyone with statins meeting
JUPITER criteria may not precisely match clinical risk with
therapy (90). Although the cost of hsCRP testing is
approximately $20 (91), which is similar to standard lipid
evaluations and less than other potential biomarkers, models
have suggested that risk-based treatment without hsCRP
testing would prove more cost effective than the addition of
Figure 5 Rate of Primary Endpoint in the JUPITER Trial
Incidence rate of the primary endpoint among (A) men and (B) women in the rosuvastatin and placebo arm of the JUPITER trial. Adapted and modiﬁed with permission from
Ridker et al. (85). Abbreviations as in Figures 2 and 3.
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405another test, given the increasing availability of low-cost
statins and recent patent expirations (92).
Although hsCRP is commonly used clinically to raise risk
estimates, it cannot be used to rule out disease because of its
poor sensitivity and low negative predictive value. Recom-
mendations for routine biomarker measurement may beneﬁt
from meticulous appropriate use criteria as those that have
recently emerged for noninvasive and invasive imaging.
Ultimately, to test the inﬂammatory hypothesis of
atherosclerosis, without reducing LDL-C is to directly
randomize patients to targeted anti-inﬂammatory thera-
pies. Two clinical trials that will test this hypothesis are
underwaydone using methotrexate and another using an
IL-1b inhibitor, canakinumab (Table 1) (93,94).Table 1 Ongoing Trials of Anti-Inﬂammatory Therapies for Atheroscle
Clinical Trial (#) Study Population Study Arms
CANTOS (NCT01327846) 17,200 patients with
history of MI on statins
with hsCRP 2 mg/l
Randomized to 3 distin
doses of quarterly
subcutaneous
canakinumab or
placebo
CIRT (NCT01594333) 7,000 patients with
history of MI and
persistent elevation of
hsCRP with type 2
diabetes mellitus or
metabolic syndrome
Randomized to
methotrexate 10 mg
weekly or placebo on
a background of fola
therapy
CANTOS ¼ Cardiovascular Risk Reduction Study Reduction in Recurrent Major CV Disease Events; CIR
C-reactive protein; MI ¼ myocardial infarction; UA ¼ unstable angina.Guideline Recommendations
A number of professional organizations and agencies have
published guidelines and recommendations on use of
hsCRP in the primary prevention of CHD (Table 2)
(41,95–98). The guidelines emphasize the lack of deﬁni-
tive data establishing a causal relationship and the loss of
predictive power of CVD endpoints when standard CVD
risk factors are accounted for. The 2010 American Heart
Association guidelines are the most favorable, giving a class
IIa designation for measurement of hsCRP in asymp-
tomatic individuals. In the absence of true statin effect
modiﬁcation by hsCRP level, the ultimate beneﬁt from
statin therapy must depend on absolute risk, to whichrosis
Phase Primary Endpoint Secondary Endpoints
ct III MI, stroke, or CV death at
3 years
MI, stroke, CV death,
revascularization for UA
Total mortality
Diabetes
te
III Recurrent MI, stroke, or
CV death at 4 years
All-cause mortality,
hospitalization for
heart failure, incidence
of venous
thromboembolism,
atrial ﬁbrillation,
diabetes, or coronary
revascularization
T ¼ Cardiovascular Inﬂammation Reduction Trial; CV ¼ cardiovascular; hsCRP ¼ high-sensitivity
Table 2 Professional Society Recommendations for hsCRP Testing
Professional Society Year Author, Journal Designation Recommendation for CRP screening
USPSTF 2009 USPSTF-AHRQ, Ann Intern Med Grade insufﬁcient (I) Insufﬁcient evidence to support the role of hsCRP in
preventive screening of asymptomatic patients
CCS 2009 Genest et al., Can J Cardiol Class IIa, Level B Men >50 years and women >60 years who are intermediate
risk by Framingham criteria and would not otherwise
qualify for lipid-lowering therapy (LDL-C <135 mg/dl)
ESC 2012
2009
Perk et al., Eur Heart J
Mancia et al., J Hypertens
Class IIb, Level B
Class III, Level B
d
Patients with moderate or unusual CVD risk proﬁle
Asymptomatic low-risk and high-risk patients to assess
10-year risk of CVD
Patients with hypertension categorized as intermediate risk
by Framingham criteria
ACC/AHA 2010 Greenland et al., J Am Coll Cardiol Class IIa, Level B
Class IIb, Level B
Class III, Level B
Men >50 years and women >60 years with
LDL-C <130 mg/dl, not on lipid-lowering therapy and
without chronic kidney disease, diabetes, or hormone
replacement therapy
Reasonable to test in asymptomatic intermediate-risk
patients.
No beneﬁt in asymptomatic high-risk or younger low-risk
patients
ACC/AHA ¼ American College of Cardiology/American Heart Association; AHRQ ¼ Agency for Healthcare Research and Quality; CCS ¼ Canadian Cardiovascular Society; CVD¼ cardiovascular disease; ESC ¼
European Society of Cardiology; USPSTF ¼ U.S. Preventive Services Task Force; LDL-C ¼ low-density lipoprotein cholesterol; other abbreviation as in Table 1.
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406hsCRP only modestly adds over traditional clinical metrics
already in use. The lack of a uniﬁed recommendation
speaks to the plethora of compelling but ultimately
inconclusive data regarding the clinical utility of hsCRP at
this time.Conclusions
During the last decade, a number of biomarkers have been
considered in the assessment of risk for prevention of CVD.
The costs and risks of screening and potentially treating
large populations are substantial. Therefore, considerable
scrutiny has been applied to determining a candidate that
materially adds to established models of risk assessment and
modiﬁcation. hsCRP, an inﬂammatory factor with wide
variability among various ages, sexes, and ethnicities, is
modestly associated with CVD. The addition of hsCRP
level to FRS results in mild improvement in risk discrimi-
nation and reclassiﬁcation largely because of the high
correlation of hsCRP with the risk factors already in the
model. Its long-term predictive capacity is likely a reﬂection
of the inﬂammatory process associated with atherosclerotic
risk.
Careful review of the available data from experimental
research, epidemiological studies, and large clinical trials
does not provide conclusive evidence for the routine testing
of hsCRP in risk prediction and as a tool to initiate statin
therapy. Statins are likely to mutually beneﬁt individuals
with or without elevated hsCRP levels. Further, the use of
achieved hsCRP level to guide the intensity of lipid-
modifying therapy is a hypothesis that is as yet unproven
as a strategy. At this time, the existing evidence remains
insufﬁcient to justify widespread use of hsCRP in clinical
practice. It may be time to remove hsCRP from the list of
potential bandits of atherosclerosis. Further investigation
with anti-inﬂammatory therapies may help bring vascularinﬂammation closer to the bedside and reﬁne the role of
hsCRP as a therapeutic target in preventing CVD.
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